Dr. Reddy's Laboratories Limited (NYSE:RDY) Q1 2025 Earnings Conference Call July 27, 2024 7:00 AM ET Conference Call Participants I now hand the conference over to Mr. Richa Periwal. Thank you and over to you. Richa Periwal - Head of Investor Relations Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer MV Narasimham - Deputy Chief Financial Officer Operator Richa Periwal Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. ...

The strategic move is set to further strengthen Dr. Reddy's OTC business. Please note that Haleon's Nicotinell is the world's second-largest brand in the NRT category, excluding the United States. It holds either the first or second position in 14 out of the top 17 global markets, with its lozenge/mini lozenge format being the top choice globally. Additionally, Nicotinell is among the top 15 OTC brands in Europe (excluding Russia and Italy) and ranks 32nd among all OTC brands globally (excluding the United ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Num ...

Dr. Reddy's Laboratories (RDY) announced entering into a license and supply agreement with Iceland-based partner, Alvotech (ALVO) , for the commercialization of AVT03. AVT03, a human monoclonal antibody, is Alvotech's biosimilar candidate to Amgen's Prolia and Xgeva (denosumab). Both Prolia and Xgeva are currently approved to treat various indications, including osteoporosis in postmenopausal women and prevention of skeletal-related events in adults with advanced malignancies. The collaboration agreement se ...

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Richa Periwal - Head of Investor Relations GV Prasad - Co-Chairman and Managing Director Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Neha Manpuria - Bank of America Merrill Lynch Kunal Dhamesha - Macquarie Capital Securities Saion Mukherjee - Nomura Securities Tarang Agrawal - Old Bridge Capital Tushar Manudhane - Motilal Os ...

Company Participants Conference Call Participants Operator I now hand the conference over to Ms. Richa Periwal. Thank you, and over to you, Ma'am. Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. Reddy's earnings conference call for the quarter ended, December 31, 2023. Earlier during the day, we've released our results and the same was also posted on our website. This call is being recorded and the playback and transcript shall be made available o ...

Dr ReddyÂ's Laboratories Ltd (NYSE:RDY) Q2 2024 Earnings Conference Call October 27, 2023 10:00 AM ET Company Participants Richa Periwal - IR Parag Agarwal - CFO Erez Israeli - CEO Conference Call Participants Mikaela Franceschina - Barclays Bank Kunal Dhamesha - Macquarie Research Neha Manpuria – Bank of America Merrill Lynch Gagan Thareja - ASK Investment Managers Aman Vij - Astute Investment Management Damayanti Kerai - HSBC Surya Patra - PhillipCapital Saion Mukherjee - Nomura Securities Tushar Manudhan ...

All amounts in millions, except EPS 7 Computation of capital employed 8 Conference Joining Information | --- | --- | --- | |-------------------------------------------------------------------------|-------------------------------------|-------------| | Option 2: Join through below Dial-In Numbers \nUniversal Access Number: | +91 22 6280 1219 \n+91 22 7115 8120 | | | | | | | | USA: 1 866 746 2133 | | | International Toll Free | UK: 0 808 101 1573 | | | Number: | Singapore: 800 101 2045 | | | | Hong Kong: | 8 ...

Dr Reddy's Laboratories Ltd (NYSE:RDY) Q1 2024 Earnings Conference Call July 26, 2023 10:00 AM ET Conference Call Participants Ladies and gentlemen, good day and welcome to the Dr. Reddy's Q1 FY '24 Earnings Call. [Operator Instructions]. Thank you Darwin. Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. Reddy's earnings conference call for the quarter ended June 30, 2023. Earlier during the day we have released our results and the same is also pos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F |  | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | |  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the Fiscal Year Ended March 31, 2023 | | | OR | |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | |  | SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...